Sobi Maintains Grip On RSV Market – For Now
Though Competition Is Coming
Executive Summary
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.
You may also be interested in...
Sobi Exits Nirsevimab Cost-Sharing Pact With AstraZeneca, Simplifies Royalty Deal With Sanofi
Deal Snapshot: Approved in the EU/UK and nearing a US approval, rights to the RSV prophylaxis for infants and newborns are simplified in the pair of agreements unveiled by Synagis owner Sobi.
Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
Sobi To Start Selling Zynlonta After Sealing EU Approval
Five months after paying $55m upfront to Switzerland's ADC Therapeutics, Sobi has been granted conditional marketing authorization for Zynlonta for the treatment of relapsed or refractory diffuse large B-cell lymphoma.